Do More With Reuters
Partner Services

India Ranbaxy gets FDA nod for cyclobenzaprine HCL

Thu May 15, 2008 9:02am IST
 
Email | Print | | Single Page
[-] Text [+]

MUMBAI, May 15 (Reuters) - Indian drugmaker Ranbaxy Laboratories Ltd (RANB.BO: Quote, Profile, Research) has received approval from the U.S. Food and Drug Administration for muscle relaxant cyclobenzaprine hydrochloride tablets, the regulator's website showed.

The FDA has also granted tentative approval to Lupin Pharmaceuticals Inc, a unit of Lupin Ltd (LUPN.BO: Quote, Profile, Research), for ramipril capsules, used in treating cardiovascular disease and high blood pressure. (Reporting by Rina Chandran; Editing by John Mair)

Britain's Prime Minister Gordon Brown speaks, as finance minister Alistair Darling listens at the G20 Finance Ministers meeting in St. Andrews, Scotland. REUTERS/POOL New
UK joins G20 push for world levy on banks

Britain threw its weight behind proposals to impose a global levy on banks to fund future bailouts and called on the G20 to work toward a $100 billion deal to meet the cost of climate change.  Full Article | Full Coverage 

special coverage

Photo
Central Banks Cautious

Reuters tracks the policies of the world's top central banks as the debate over global economic recovery rages on.  Full Coverage 

Market Update

  • IndiaIndia
  • USUS
  • UKUK
  • Asia
  • Most Actives

column

Nipun Mehta
Nipun Mehta, SG Private Banking
India - planning the road to recovery

There needs to be an acceptable balance created between education & healthcare and infrastructure spend.  Full Article 

SHOWCASE

Robot Asimo

Snapshots of Honda Motor's humanoid robot Asimo  Slideshow 

 
Marketing Strategy
Marketing Strategy

Companies are now using direct marketing methods to sell their products.  Full Article 

 
Out of Woods?
Out of the Woods?

Analysis - CIT's bankruptcy exit fraught with uncertainty  Full Article 

 
Exit Plans
Exit Plans

Factbox - Stimulus exit plans for Asia-Pacific's big 5 economies  Full Article